Replies to post #11591 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: Thrombate (plasma-derived AT) production plans

Following is an excerpt from the mid-2007 SEC papers filed by Talecris to
support an IPO. (As LRG pointed out, the IPO plans have been rescinded.)

http://www.sec.gov/Archives/edgar/data/1405197/000104746907005901/a2178655zs-1.htm [page 113, emphasis added]

>>
…we are working to transfer production of our product Thrombate III Antithrombin III from Bayer, with whom we have a supply agreement through 2008, with an option to extend through 2009. We anticipate shifting production of Thrombate III Antithrombin III to our facilities by 2011, which we expect will allow for further volume increases. We are continuing to assess Thrombate III Antithrombin III for potential therapies in the areas of cardiovascular, transplant, and sepsis.
<<

In other words, Talecris won’t be able to materially expand production of Thrombate for a few years. Obviously, this is good for GTC and its US partner.

p.s. Interesting that the above excerpt mentions sepsis.